Literature DB >> 8885928

High failure rate of postmortem karyotyping after termination for fetal abnormality.

P M Kyle1, W Sepulveda, S Blunt, G Davies, P M Cox, N M Fisk.   

Abstract

OBJECTIVE: To determine the failure rate of karyotyping from samples taken after termination of pregnancy for fetal abnormality.
METHODS: Perinatal autopsy reports over a 12-month period were reviewed to identify those with cytogenetic studies performed after termination of pregnancy for fetal abnormality.
RESULTS: During the audit period, there were 104 terminations for fetal abnormality. In 89 fetuses, fetal skin (n = 85), placenta (n = 62), or other samples (n = 8) were obtained for postmortem cytogenetic analysis. In 24 (27%) fetuses, postmortem tissues did not yield a karyotype result. The failure rate of post-termination karyotyping was significantly influenced by delivery-sampling interval, but not by gestational age, type of tissue sampled, use of potassium chloride, or aneuploidy. Of the 24 cases for which no post-termination karyotype was obtained, 16 had had successful pre-termination karyotyping, resulting in only eight of 89 (9%) cases in the overall series not having a final karyotype.
CONCLUSION: The high failure rate for post-termination karyotyping suggests that a pre-termination procedure is necessary if parents wish to have almost 100% certainty that cytogenetic information will be available for later genetic counseling.

Entities:  

Mesh:

Year:  1996        PMID: 8885928     DOI: 10.1016/0029-7844(96)00311-0

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  2 in total

1.  Induction of labor compared to dilation and evacuation for postmortem analysis.

Authors:  A K Lal; M A Kominiarek; N M Sprawka
Journal:  Prenat Diagn       Date:  2014-03-18       Impact factor: 3.050

Review 2.  Isolated mild fetal ventriculomegaly.

Authors:  M Wyldes; M Watkinson
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2004-01       Impact factor: 5.747

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.